Results for tag: "Mucormycosis Drug"

Mucormycosis is a rare but serious fungal infection caused by a group of molds called mucormycetes. It is most commonly seen in people with weakened immune systems, such as those with diabetes, cancer, or HIV/AIDS. Treatment for mucormycosis typically involves a combination of antifungal medications and surgery. The mucormycosis drug market is a subset of the larger infectious diseases drug market. It is composed of antifungal medications used to treat mucormycosis, as well as other drugs used to manage the symptoms of the infection. These drugs are typically administered orally or intravenously, depending on the severity of the infection. The mucormycosis drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and Johnson & Johnson. Other companies, such as Cipla, Mylan, and Lupin, also offer antifungal medications for the treatment of mucormycosis. Show Less Read more